



#3 PCT
JC10 Rec'd PCT/PTO 09 MAY 2005

PATENT
ATTORNEY DOCKET NUMBER: 50125/100001

Certificate of Mailing: Date of Deposit: 5/5/05

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Coyne
Printed name of person mailing correspondence

Colleen Coyne
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark Burcin et al.

Art Unit:

Serial No.: 10/530,988

Examiner:

Filed: April 12, 2005

Customer No.: 21559

Title: TRANSPLANTABLE CELL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed within three months of the filing date of the application.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.


Respectfully submitted,

Date: 05 May 2005



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))	Attorney Docket No.	50125/100001
	Serial No.	10/530,988
	Applicant	Mark Burcin et al.
	Filing Date	
	Group	Not yet assigned
	IDS Filed	May 5, 2005
	Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,912,411	06/15/99	Bujard et al.			
	5,750,825	05/12/98	Yazaki et al.			
	5,733,727	03/31/98	Field			
	5,698,765	12/16/97	Mak			
	5,625,122	04/29/97	Mak			
	5,583,278	12/10/96	Alt et al.			
	5,175,103	12/29/92	Lee et al.			
	4,736,866	04/12/88	Leder et al.			


FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/87330 A2	11/22/01	WIPO			
	WO 01/71006 A2	09/27/01	WIPO			
	WO 01/40494 A1	06/07/01	WIPO			
	WO 01/32855 A1	05/10/01	WIPO			
	WO 00/64459 A1	11/02/00	WIPO			
	WO 00/12138 A2	03/09/00	WIPO			
	WO 00/12741 A2	03/09/00	WIPO			Abstract
	WO 97/41232 A1	11/06/97	WIPO			
	WO 97/36052 A2	10/02/97	WIPO			
	WO 97/11689 A1	04/03/97	WIPO			Abstract
	WO 96/26274 A1	08/29/96	WIPO			


EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50125/100001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 C.F.R. §1.98(b))		Serial No.	10/530,988	
				Applicant	Mark Burcin et al.	
				Filing Date	Not yet assigned	
				Group	May 5, 2005	
				IDS Filed	21559	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 944 398 B1	04/07/04	EPO – Europe			
	EP 0 916 336 A1	05/19/99	EPO – Europe			
	EP 0 889 723 A1	06/05/02	EPO – Europe			
	EP 0 417 563 B1	07/05/00	EPO – Europe			Claims
	DE 196 25 049 A1	01/02/98	DE – Germany			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucl. Acids Res.</i> 25:3389-3402 (1997).						
Behr et al., "Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA," <i>Proc. Natl. Acad. Sci. USA</i> 86:6982-6986 (1989).						
Beveridge et al., "Lymphomas and lymphoproliferative lesions developing under cyclosporine therapy," <i>Lancet</i> 1:788 (1984).						
Bonini et al., "HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia," <i>Science</i> 276:1719-1724 (1997).						
Brandén et al., "A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA," <i>Nat. Biotechnol.</i> 17:784-787 (1999).						
Burcin et al., "A regulatory system for target gene expression," <i>Front. Biosci.</i> 3:c1-7 (1998).						
Chao et al., "mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway is one component of the GM-CSF viability response," <i>Mol. Cell. Biol.</i> 18:4883-4898 (1998).						
Corry et al., "Primarily vascularized allografts of hearts in mice," <i>Transplantation</i> 16:343-350 (1973).						
Felgner et al., "Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations," <i>J. Biol. Chem.</i> 269:2550-2561 (1994).						
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50125/100001
				Serial No. 10/530,988
				Applicant Mark Burcin et al.
				Filing Date
				Group Not yet assigned
				IDS Filed May 5, 2005
				Customer No. 21559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				
(37 C.F.R. §1.98(b))				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)				
	Ferrari-Lacraz et al., "An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection," <i>J. Immunol.</i> 167:3478-3485 (2001).			
	Früh et al., "A viral inhibitor of peptide transporters for antigen presentation," <i>Nature</i> 375:415-418 (1995).			
	Gossen et al., "Inducible gene expression systems for higher eukaryotic cells," <i>Curr. Opin. Biotechnol.</i> 5:516-520 (1994).			
	Gossen et al., "Transcriptional activation by tetracyclines in mammalian cells," <i>Science</i> 268:1766-1769 (1995).			
	Gossen and Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," <i>Proc. Natl. Acad. Sci. USA</i> 89:5547-5551 (1992).			
	Halappanavar et al., "Survival and proliferation of cells expressing caspase-uncleavable poly(ADP-ribose) polymerase to death-inducing DNA damage by an alkylating agent," <i>J. Biol. Chem.</i> 274:37097-37104 (1999).			
	Jones et al., "Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1," <i>Nature</i> 323:346-349 (1986).			
	Khromykh, "Replicon-based vectors of positive strand RNA viruses," <i>Curr. Opin. Mol. Ther.</i> 2:555-569 (2000).			
	Kichler et al., "Influence of membrane-active peptides on lipospermine/DNA complex mediated gene transfer," <i>Bioconj. Chem.</i> 8:213-221 (1997).			
	Kim et al., "Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity," <i>J. Immunol.</i> 160:5742-5748 (1998).			
	Klug et al., "Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts," <i>J. Clin. Invest.</i> 98:216-224 (1996).			
	Koh et al., "Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis," <i>J. Clin. Invest.</i> 95:114-121 (1995).			
	Lindemann et al., "Versatile retrovirus vector systems for regulated gene expression <i>in vitro</i> and <i>in vivo</i> ," <i>Mol. Med.</i> 3:466-476 (1997).			
	Linstedt et al., "Sequence and overexpression of GPP130/GIMPC: evidence for saturable pH-sensitive targeting of a type II early golgi membrane protein," <i>Mol. Biol. Cell.</i> 8:1073-1087 (1997).			
	Mehlen et al., "The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis," <i>Nature</i> 395:801-804 (1988).			
	Ono and Lindsey, "Improved technique of heart transplantation in rats," <i>J. Thorac. Cardiovasc. Surg.</i> 57:225-229 (1969).			
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.				



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/100001
		Serial No.	10/530,988
		Applicant	Mark Burcin et al.
		Filing Date	Not yet assigned
		Group	Not yet assigned
		IDS Filed	May 5, 2005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	(37 C.F.R. §1.98(b))	Customer No.	21559
		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Penn, I., "Occurrence of cancers in immunosuppressed organ transplant recipients," <i>Clin. Transpl.</i> 147-158 (1998).		
	Penn, I., "The changing pattern of posttransplant malignancies," <i>Transplant Proc.</i> 23:1101-1103 (1991).		
	Plank et al., "The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems," <i>J. Biol. Chem.</i> 269:12918-12924 (1994).		
	Pleasure et al., "Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons," <i>J. Neurosci.</i> 12:1802-1815 (1992).		
	Rivera et al., "A humanized system for pharmacologic control of gene expression," <i>Nat. Med.</i> 2:1028-1032 (1996).		
	Rizzu et al., "Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients," <i>Hum. Mol. Genet.</i> 9:3075-3082 (2000).		
	Schwartz et al., "Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer <i>in vitro</i> and <i>in vivo</i> ," <i>Gene Ther.</i> 6:282-292 (1999).		
	Shapiro et al., "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen," <i>N. Engl. J. Med.</i> 343:230-238 (2000).		
	Soria et al., "Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice," <i>Diabetes</i> 49:157-162 (2000).		
	Springer et al., "VEGF gene delivery to muscle: potential role for vasculogenesis in adults," <i>Mol. Cell.</i> 2:549-558 (1998).		
	Strom et al., "Allogeneic stem cells, clinical transplantation, and the origins of regenerative medicine," <i>Transplantation Proc.</i> 33:3044-3049 (2001).		
	Uhlmann and Peyman, "Antisense oligonucleotides: a new therapeutic principle," <i>Chem. Rev.</i> 90:544-584 (1990).		
	van der Vlag et al., "Transcriptional repression mediated by polycomb group proteins and other chromatin-associated repressors is selectively blocked by insulators," <i>J. Biol. Chem.</i> 275:697-704 (2000).		
	Wang et al., "Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator," <i>Gene Ther.</i> 4:432-441 (1997).		
	Wang et al., "A regulatory system for use in gene transfer," <i>Proc. Natl. Acad. Sci. USA</i> 91:8180-8184 (1994).		
	Zhou and Huang, "DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action," <i>Biochim Biophys Acta.</i> 1189:195-203 (1994).		
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			